Media headlines about Horizon Pharma (NASDAQ:HZNP) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Horizon Pharma earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.0395119427026 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Zacks: Analysts Anticipate Horizon Pharma PLC (HZNP) Will Announce Quarterly Sales of $267.58 Million (americanbankingnews.com)
- Horizon Pharma: Primary Care Segment Remains A Burden And … – Seeking Alpha (seekingalpha.com)
- Horizon Pharma (HZNP) PT Raised to $19 at Goldman Sachs Following Management Meetings; ‘Entering Next Phase … – StreetInsider.com (streetinsider.com)
- Horizon Pharma plc to Present at the 36th Annual JP Morgan Healthcare Conference – GlobeNewswire (press release) (globenewswire.com)
- Free Research Report as Horizon Pharma’s Revenue Grew 30.2% (finance.yahoo.com)
Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald set a $17.00 price objective on shares of Horizon Pharma and gave the stock a “buy” rating in a research note on Friday, December 1st. Jefferies Group increased their price objective on shares of Horizon Pharma from $16.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, November 7th. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price objective on shares of Horizon Pharma in a research note on Sunday, October 22nd. Piper Jaffray Companies set a $18.00 price objective on shares of Horizon Pharma and gave the stock a “buy” rating in a research note on Sunday, October 15th. Finally, UBS set a $20.00 price objective on shares of Horizon Pharma and gave the stock a “buy” rating in a research note on Thursday, November 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company’s stock. Horizon Pharma presently has an average rating of “Buy” and a consensus price target of $18.75.
Horizon Pharma (NASDAQ:HZNP) last posted its earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.22 by $0.04. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The firm had revenue of $271.60 million during the quarter, compared to analysts’ expectations of $259.74 million. During the same quarter in the prior year, the firm earned $0.70 EPS. Horizon Pharma’s quarterly revenue was up 30.1% on a year-over-year basis. analysts expect that Horizon Pharma will post 0.72 EPS for the current year.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.